Global HPV Associated Disorders Market Share 2024, Forecast To 2033
21 Feb, 2024
The market for HPV-associated disorders has surged, growing from $19.42 billion in 2023 to $20.97 billion in 2024, reflecting an 8.0% CAGR. This growth is attributed to heightened awareness, advancements in diagnostics, and government initiatives. Anticipated expansion to $27.82 billion in 2028, with a 7.3% CAGR, is driven by new vaccines, increased screening, and integration into routine healthcare. Notable trends include next-gen vaccines and personalized approaches.
Global HPV Associated Disorders Market Key Driver
The HPV-associated disorders market is expected to grow due to the increased prevalence of HPV-related cases. These disorders range from benign verrucae vulgates to malignancies in various body parts. Notably, women worldwide face a substantial proportion of HPV infections, leading to conditions like cervical cancer. In 2022, an estimated 14,100 women in the U.S. will be diagnosed with invasive cervical cancer. Additionally, 604,127 women globally were diagnosed with cervical cancer in 2020, with 4,310 deaths from cervical cancer in the U.S. in 2023. Hence, the rising HPV cases contribute to the growth of the HPV-associated disorders market.
Get A Free Sample Of The Global HPV Associated Disorders Market ReportGlobal HPV Associated Disorders Market Segments
The hpv associated disorders market covered in this report is segmented –
1)By Indication: Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer, Anal Intraepithelial Neoplasia (AIN), Anal Cancer, Genital Warts, Other Indications
2)By Therapy: Prevention, Treatment
3)By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: The regions covered in the template market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the HPV associated disorders market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hpv associated disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major HPV Associated Disorders Industry Players
AstraZeneca plc; F. Hoffmann-La Roche Ltd; Biocon Ltd; GlaxoSmithKline plc; Merck & Co Inc.; Pfizer Inc.; Eli Lilly and Company; Sanofi S. A.; Novartis AG; Bristol-Myers Squibb Company; Johnson & Johnson Inc.; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Amgen Inc.; Biogen Inc.; Celgene Corporation; Gilead Sciences Inc.; Ipsen S. A.; Mylan N. V.; Teva Pharmaceutical Industries Ltd.; Bayer AG; Eisai Co. Ltd.; Genentech Inc.; Medtronic plc; Novo Nordisk A/S; Siemens Healthineers AG; Thermo Fisher Scientific Inc.; Quest Diagnostics Incorporated; CSL Limited; Lupin Limited
Get The Full Global HPV Associated Disorders Market Report
HPV Associated Disorders Market Overview
The human papillomavirus-associated disorders refer to a virus that can induce aberrant tissue growth such as warts and other cell abnormalities. These disorders are mainly transmitted by sexual intercourse or other forms of skin-to-skin contact. Vaccines, medication, and other diagnoses can help protect against HPV types that cure HPV cancer.
HPV Associated Disorders Global Market Report 2023 provides data on the global hpv associated disorders market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The hpv associated disorders market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.